Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services Division (MCSD). MPD provides retail pharmacy and mail-order pharmacy services related to COVID-19, antibiotics, dermatology, family medicine, immunology, neurology, pain management, pediatrics, preventive medicine and psychiatry to patients in Southern California. MCSD provides licensed healthcare through a clinic in Brea, California, United States. MCSD is focused on developing a telehealth platform, which connects patients with physicians, and facilitates and manages the provision of virtual consultation, diagnosis, and treatment services in partnership with qualified health practitioners.


OTCPK:MEDVF - Post by User

Post by Hiddensecretson Jul 27, 2021 5:08pm
211 Views
Post# 33614059

FOLLOW the MONEY: $ 12 million (hints at big REVENUE)

FOLLOW the MONEY: $ 12 million (hints at big REVENUE)As a shareholder I torn between two choices:

(a) Look at the chart, look at the developments and come to a conclusion that MEDV is a failure.

or, 

(b) Follow the money, ignore the chart and developments and, come to a conclusion that MEDV is successful.

Shareholders are selling their stock because they are in the dark and have concluded that option (a) applies.

But, insiders are loading up on the stock some $ 12 millionn because they have concluede that option (b) applies.

For myself, I have learned to follow the MONEY TRAIL even though there is no visibility at this moment for the shareholders.

I have to trust that Stan Bharti and his associates would not throw away $ 12 million if they did not have a place of action or, vision to ensure that they will get their month back and, more. 

David Preiner is very quiet but he is not idle.   He will not talk hot air like Doug did.   He is organizing his vision of the future with MEDV. 

This is what I have understood that they are doing at the moment:

They started with covid19 testing to establish a base of clients and, a base of outlets where you can get tested.  They have now expanded their product offerings to include:   adxit test score, vaccines, issuance of medication through a pharmacy, mobile health care using Artificial intelligence and delivered through the Myosin app (a health care platform) which they purchased to have doctors treat patients, to funding blowfish through tests and then launching product around USA with all employers.


You can see that they have expanded their product platforms and beyond covid19 towards mobile health care. 

Because it will encompass many services, the revenue generated per patient will be in the $ 300 to $ 500 per year, which means you will need less patients to survive and, also that gross margins will be through the roof. 

As David said, their service will be a one stop shopping as if you go to Star Bucks or, Tim Hortons. 

Q2 is a transmational period however for Q3 that ends September 2021 we will see a strong balance sheet with good revenue numbers which will only accelerate by Q4.

Treat this investment as an RRSP purchase at the moment, meaning put your shares away and look at them in 6 months.   Then you have reconsider your position.

mpo


<< Previous
Bullboard Posts
Next >>